PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lu, Yan ^a,b   Zhang, Teng Fei ^a,b   Shi, Yue ^a,b   Zhou, Han Wei ^a,b   Chen, Qi ^a,b   Wei, Bu Yun ^a,b   Wang, Xi ^c   Yang, Tian Xin ^d   Chinn, Y Eugene ^e   Kang, Jian ^f   Fu, Cai Yun ^a,b,g  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine   (China)

^c The 117th Hospital of Chinese PLA   (China)

^d ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Key Laboratory of Cell Based Drug and Applied Technology Development   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; LACTOFERRIN; PEPTIDE;

ANIMAL; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; HEMOLYSIS; HL-60 CELL LINE; HUMAN; LEUKEMIA; MOUSE; NECROSIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HEMOLYSIS; HL-60 CELLS; HUMANS; LACTOFERRIN; LEUKEMIA; MICE; NECROSIS; PEPTIDES;

EID: 84958073782     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20823     Document Type: Article

References (57)

1. Mendez-Samperio, P. Recent advances in the field of antimicrobial peptides in inflammatory diseases. Adv Biomed Res. 2, 50 (2013).
2. Devine, D. A., Hancock, R. E. Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des. 8, 703-714 (2002).
3. Zeya, H. I.,Spitznagel, J. K. Antibacterial and Enzymic Basic Proteins from Leukocyte Lysosomes: Separation and Identification. Science. 142, 1085-1087 (1963).
4. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature. 415, 389-395 (2002).
5. Hancock, R. E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis.1, 156-164 (2001).
6. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol, 3, 238-250 (2005).
7. Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. New Engl J Med. 347, 1151-1160(2002).
8. Bahar, A. A.,Ren, D. Antimicrobial peptides. Pharmaceuticals. 6, 1543-1575 (2013).
9. Hoskin, D. W.,Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochimica et Biophysica Acta. 1778, 357-375 (2008).
10. Gaspar, D., Veiga, A. S.,Castanho, M. A. From antimicrobial to anticancer peptides. A review. Front Microbiol. 4, 294 (2013).
11. Pierce, A.,Legrand, D. Advances in lactoferrin research. Biochimie. 91, 1-2 (2009).
12. Masson, P. L., Heremans, J. F.,Schonne, E. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med. 130, 643-658 (1969).
13. Yamauchi, K., Tomita, M., Giehl, T. J., Ellison, R. T., 3rd. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun. 61, 719-728 (1993).
14. Bellamy, W., Takase, M., Wakabayashi, H., Kawase, K., Tomita, M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Microbiol. 73, 472-479 (1992a).
15. Ellison, R. T., 3rd. The effects of lactoferrin on gram-negative bacteria. Adv Clin Exp Med. 357, 71-90 (1994).
16. Bellamy, W. et al. Identification of the bactericidal domain of lactoferrin. Biochimica et Biophysica Acta. 1121, 130-136 (1992b).
17. Orsi, N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals. 17, 189-196(2004).
18. Arnold, R. R., Cole, M. F., McGhee, J. R. A bactericidal effect for human lactoferrin. Science. 197, 263-265 (1977).
19. Bortner, C. A., Miller, R. D., Arnold, R. R. Bactericidal effect of lactoferrin on Legionella pneumophila. Infect Immun. 51, 373-377 (1986).
20. Gifford, J. L., Hunter, H. N., Vogel, H. J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life S. 62, 2588-2598 (2005).
21. Mader, J. S., Salsman, J., Conrad, D. M.,Hoskin, D. W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 4, 612-624 (2005).
22. Mader, J. S. et al. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res. 313, 2634-2650 (2007).
23. Eliassen, L. T. et al. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer. 119, 493-500 (2006).
24. Eliassen, L. T. et al. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 22, 2703-2710 (2002).
25. Yoo, Y. C. et al. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Bioph Res Co. 237, 624-628 (1997).
26. Wakabayashi, H., Takase, M., Tomita, M. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des. 9, 1277-1287 (2003).
27. Sanchez-Gomez, S. et al. Comparative analysis of selected methods for the assessment of antimicrobial and membranepermeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol. 8, 196 (2008).
28. Sawyer, T. K., Chorev, M. Peptide revolution: genomics, proteomics and therapeutics. Bio Techniques. 34, 594-599 (2003).
29. Zweytick, D. et al. Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity. Biochimica et Biophysica Acta. 1758, 1426-1435 (2006).
30. Zweytick, D. et al. Studies on lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. J Biol Chem. 286, 21266-21276 (2011).
31. Oreopoulos, J., Epand, R. F., Epand, R. M., Yip, C. M. Peptide-induced domain formation in supported lipid bilayers: direct evidence by combined atomic force and polarized total internal reflection fluorescence microscopy. Biophy J. 98, 815-823 (2010).
32. Epand, R. M. et al. Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochimica et Biophysica Acta. 1798, 1272-1280 (2010).
33. Zorko, M., Japelj, B., Hafner-Bratkovic, I., Jerala, R. Expression, purification and structural studies of a short antimicrobial peptide. Biochimica et Biophysica Acta. 1788, 314-323 (2009).
34. Zhu, L. N. et al. Novel cytotoxic exhibition mode of antimicrobial peptide anoplin in MEL cells, the cell line of murine Friend leukemia virus-induced leukemic cells. J Pept Sci. 19, 566-574 (2013).
35. Yu,T., Malugin, A., Ghandehari, H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. Acs Nano. 5, 5717-5728 (2011).
36. Wang, G., Li, X., Wang, Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37, D933-937 (2009a).
37. Xia, R. L. et al. Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel. Onco Rep. 30, 1853-1859 (2013).
38. Taimor, G., Lorenz, H., Hofstaetter, B., Schluter, K. D., Piper, H. M. Induction of necrosis but not apoptosis after anoxia and reoxygenation in isolated adult cardiomyocytes of rat. Cardiovasc Res. 41, 147-156 (1999).
39. Richards, W. L. et al. Measurement of cell proliferation in microculture using Hoechst 33342 for the rapid semiautomated micro fluorimetric determination of chromatin DNA. Exp Cell Res. 159, 235-246 (1985).
40. Chen, Y. W. et al. Inorganic mercury causes pancreatic beta-cell death via the oxidative stress-induced apoptotic and necrotic pathways. Toxicol Appl Pharm. 243, 323-331 (2010).
41. Lopez, E., Figueroa, S., Oset-Gasque, M. J., Gonzalez, M. P. Apoptosis and necrosis: two distinct events induced by cadmium in cortical neurons in culture. Br J Pharmacol. 138, 901-911 (2003).
42. Kennedy, C. L., Smith, D. J., Lyras, D., Chakravorty, A., Rood, J. I. Programmed cellular necrosis mediated by the pore-forming alpha-toxin from Clostridium septicum. PLoS Pathog. 5, 6974-6984 (2009).
43. Han, E. K. et al. Increased expression of cyclin D1in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ. 7, 699-710 (1996).
44. Sofer-Levi, Y., Resnitzky, D. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene. 13, 2431-2437 (1996).
45. Timsit, S. et al. Increased cyclin D1 in vulnerable neurons in the hippocampus after ischaemia and epilepsy: a modulator of in vivo programmed cell death? Eur J Neurosci. 11, 263-278 (1999).
46. Pratt, M. A., Niu, M., White, D. Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids. J Cell Biochem. 90, 692-708 (2003).
47. Liang, G. M., Jiang, X. P. Positive selection drives lactoferrin evolution in mammals. Genetica. 138, 757-762 (2010).
48. Hristova, K., Dempsey, C. E., White, S. H. Structure, location, and lipid perturbations of melittin at the membrane interface. Biophys J. 80, 801-811 (2001).
49. Lehmann, J. et al. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol. 50, 141-147 (2006).
50. Spector, A. A., Yorek, M. A. Membrane lipid composition and cellular function. J Lipid Res. 26, 1015-1035 (1985).
51. Connor, J., Schroit, A. J. Transbilayer movement of phosphatidylserine in nonhuman erythrocytes: evidence that the aminophospholipid transporter is a ubiquitous membrane protein. Biochemistry. 28, 9680-9685 (1989).
52. Ran, S., Thorpe, P. E. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol. 54, 1479-1484 (2002).
53. Riedl, S. et al. In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochimica et Biophysica Acta. 1808, 2638-2645 (2011).
54. Schroder-Borm, H., Bakalova, R., Andra, J. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 579, 6128-6134 (2005).
55. Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., Fidler, I. J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51, 3062-3066 (1991).
56. Riedl, S., Rinner, B., Schaider, H., Lohner, K., Zweytick, D. Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine. Biometals. 27, 981-997 (2014).
57. Leuschner, C., Hansel, W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des. 10, 2299-2310 (2004).